Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 111; no. 11; pp. 2203 - 2204
Main Authors Choughule, A, Sharma, R, Trivedi, V, Thavamani, A, Noronha, V, Joshi, A, Desai, S, Chandrani, P, Sundaram, P, Utture, S, Jambhekar, N, Gupta, S, Aich, J, Prabhash, K, Dutt, A
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 25.11.2014
Nature Publishing Group
Subjects
631/208/737
631/92/436/434
692/699/67/1059/99
692/699/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Drug Resistance
Epidemiology
ErbB Receptors - genetics
Humans
Letter to the Editor
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Molecular Medicine
Mutation
Oncology
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins p21(ras)
ras Proteins - genetics
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2014.401